Wednesday, July 8, 2026

pharma · Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation · Myelodysplastic Syndrome · PMVP

PMV Pharmaceuticals

MV Pharmaceuticals is a pharma organization headquartered in PRINCETON, NJ, USA. It trades on NYSE under ticker PMVP. Primary therapeutic focus areas include Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y

PRINCETON, NJ, USA HQ
4 Employees
Public company Type
PMVP · NYSE Ticker
Company details
Status
Public
HQ
PRINCETON, NJ, USA
Employees
4
Programs
6
Drugs
5
Patents
11
Clinical program

rezatapopt

Phase 2 · small molecule · Advanced Solid Tumor

rezatapopt for Advanced Solid Tumor is a Phase 2 program (small_molecule) at PMV Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All PMV Pharmaceuticals projects Phase 2 small molecule active

Internal code PMV-586-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PMV Pharmaceuticals
Phase
Phase 2
Modality
small_molecule
Indication
Advanced Solid Tumor
Status
active
Trials
1

Clinical trials